News/ News/ R&D Vertex builds in gene editing yet again, with $1.2bn Arbor deal Phil Taylor Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma 0 Comment Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of Share X Vertex builds in gene editing yet again, with $1.2bn Arbor deal https://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/